MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog-and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific antimiR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/ Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC.
MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog-and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific antimiR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/
Introduction
Head and neck squamous cell carcinoma (HNSCC) is a malignancy that involves cancers of the lip, oral cavity, pharynx, hypopharynx, larynx, nose, nasal, sinuses, neck, ears and salivary glands (Parkin et al., 2005) . Advanced HNSCC is an aggressive disease associated with major morbidity and mortality. The 3-year survival rate for patients with advanced-stage HNSCC treated with standard therapy is only 30-50%. Resistance to standard therapy continues to be a limiting factor in the treatment of HNSCC. Nearly 40-60% of HNSCC patients subsequently develop chemoresistance, locoregional recurrences or distant metastases (Parkin et al., 2005; Jemal et al., 2008) . Thus, clarification of key aspects of tumor cell functions underlying the clinical behavior of HNSCC is greatly needed.
Previous studies identified specific extracellular matrix components in HNSCC that correlate with tumor cell behaviors (Wang and Bourguignon, 2011) . Among such candidate molecules is hyaluronan (HA), which is a nonsulfated, unbranched glycosaminoglycan consisting of repeating disaccharide units, D-glucuronic acid and N-acetyl-D-glucosamine (Toole and Hascall, 2002) . HA interacts with CD44, a family of cell-surface glycoprotein receptors that are also expressed in a variety of human solid neoplasms, particularly those classified as HNSCC (Wang et al., 2009) . Both CD44 and HA are overexpressed/elevated at sites of tumor attachment (Toole and Hascall, 2002; . HA binding to CD44 not only affects cell adhesion to extracellular matrix components, but also is involved in the stimulation of a variety of tumor cell-specific functions leading to cytoskeleton function and HNSCC progression (Turley et al., 2002; Bourguignon, 2008) . However, the oncogenic mechanism(s) occurring during HA-activated and CD44-specific HNSCC progression remain(s) to be determined.
The stem cell marker Nanog is an important transcription factor involved in the self-renewal and maintenance of pluripotency in the inner cell mass of mammalian embryo and of embryonic stem cells (Mitsui et al., 2003) . Nanog signaling is regulated by interactions among various pluripotent stem cell regulators (for example, Rex1, Sox2 and Oct3/4), which together control the expression of a set of target genes required for embryonic stem cell pluripotency (Mitsui et al., 2003) . These findings confirm the essential role of Nanog in regulating a variety of cellular functions. Recently, several tumor cell types have been shown to express Nanog (Ezeh et al., 2005; Bourguignon et al., 2008) . HA binding to epithelial tumor cells has been shown to promote Nanog protein association with CD44, followed by Nanog activation and the expression of pluripotent stem cell regulators (for example, Rex1 and Sox2) . These findings strongly suggest that HA/CD44 signaling and Nanog function are tightly linked.
The signal transducer and activator of transcription protein 3 (Stat-3) was initially identified as an acute phase response factor (APRF), an inducible DNA-binding protein that binds to the IL-6-responsive element within the promoters of hepatic acute phase genes (Darnell, 1997; Heinrich et al., 2003) . Accumulating evidence indicates that Stat-3 also has an important role in regulating cell growth, differentiation and survival (Huang, 2007) . Nanog and Stat-3 also appear to be both structurally linked and functionally coupled in HA/CD44 signaling during epithelial tumor cell activation . The question of whether Nanog and Stat-3 are interacting with each other in HNSCC cells will be addressed in this study.
A number of studies indicate that >50% of micro-RNA ((miRNA), small RNA molecules with B20-25 nucleotides) are located in cancer-related genomic regions or fragile sites, suggesting that miRNA may be closely associated with the pathogenesis of a variety of cancers, including HNSCC (Volinia et al., 2006; Chang et al., 2008) . Analysis of an array profile of miRNA expression in HNSCC tissues reveals that miR-21 is abundantly produced in these tumors compared with normal tissues (Volinia et al., 2006) . The functional significance of miR-21 has been elucidated in several recent studies following the discovery of its specific targets (Asangani et al., 2008) , making miR-21 one of the most-studied miRNAs owing to its involvement in cancer progression. Importantly, miR-21 has a role in the inhibition of tumor suppressor proteins such as programmed cell death 4 (PDCD4), via a conserved site within the 3 0 -untranslated region of the mRNA (Asangani et al., 2008; Bourguignon et al., 2009a) . Downregulation of PDCD4 expression by miR-21 leads to tumor cell growth, survival, chemoresistance, invasion and metastasis (Bourguignon et al., 2009a) . Thus, miR-21 is currently considered to be an oncogenic miRNA.
Whether HA/CD44-mediated Nanog (or Stat-3) signaling is involved in regulating oncogenic miRNA (for example, miR-21) expression/function and tumor-specific behaviors in HNSCC cells has not been determined, and represents the primary focus of this study.
In this study, we discovered a new matrix HA/CD44-mediated Nanog/Stat-3 signaling mechanism that regulates miR-21 production and chemoresistance in HNSCC cells. Specifically, our results indicate that HA/CD44 activates Nanog-Stat-3 signaling which, in turn, stimulates miR-21 expression and function. These events lead to the reduction of the tumor suppressor protein, PDCD4, upregulation of survival proteins and cisplatin chemoresistance in HNSCC cells. Inhibition of either Nanog/Stat-3 signaling or silencing miR-21 expression/function not only results in PDCD4 upregulation but also causes a reduction of survival protein expression and an enhancement of chemosensitivity to cisplatin. Thus, our findings strongly support the contention that Nanog, Stat-3 and miR-21 form a functional signaling axis that regulates tumor cell survival and cisplatin chemoresistance in HNSCC cells.
Results
Hyaluronan-mediated CD44 interaction with Nanog and Stat-3 in HSC-3 Cells Previous studies showed that both Nanog and Stat-3 are functionally coupled during oncogenesis . Among the signaling aberrations present in HNSCC, Stat-3 activation appears to be one of the critical pathways in HNSCC development and progression (Song and Grandis, 2000) . Cellular transformation by Stat-3 generally requires specific phosphorylation of the tyrosine 705 [pY 705 ] residue (Wen et al., 1995) . In this study, we first examined whether Nanog and Stat-3 are expressed in clinical HNSCC tissue specimens. Primary HNSCC tumors were immunostained with antibodies for Nanog, total Stat-3 and tyrosine phosphorylated Stat-3. Figure 1A shows representative examples of the immunohistochemical staining of HNSCC primary tumors for both Nanog and Stat-3 (Figure 1Aa and b). We have also observed colocalization of Nanog with tyrosine phosphorylated Stat-3 and total Stat-3 (Figures 1Ac-e and Af-h) in HNSCC patient samples. These findings clearly demonstrated that a close association between Nanog and Stat-3 (including tyrosine phosphorylated Stat-3) occurs in head and neck cancer patient samples.
HA/CD44-mediated oncogenic signaling has been implicated in both the initiation and development of several solid tumors, including head and neck cancer (Toole and Hascall, 2002; Huang, 2007; Bourguignon et al., 2008 Bourguignon et al., , 2009a Wang et al., 2009; Wang and Bourguignon, 2011) . However, the cellular and molecular mechanisms by which HA/CD44 signaling occurs in HNSCC cells are still poorly understood. In this study, we have focused on the question of whether there is a physical linkage between CD44 and tyro- ] antibody were used to examine the expression of both Nanog and Stat-3 in HNSCC primary tumors using immuno-peroxidase staining (a and b) or colocalization of Nanog with phosphorylated Stat-3 (phosphorylated Stat-3) (c-e) and total stat-3 (f-h) using double immunofluorescence staining as described in Materials and methods. (B) Time course analyses of HA/CD44-induced Stat-3 tyrosine phosphorylation: Cell lysates were prepared from HSC-3 treated with HA (50 mg/ml) for various time intervals (for example, 0, 5, 10, 15 and 60 min) followed by anti-CD44-immunoprecipitation followed by immunoblotting with anti-phospho-Stat-3 [pY 705 ] antibody or anti-CD44 antibody (as a loading control). (C) Detection of Nanog and Stat-3 (or phosphorylated Stat-3) in the CD44 complex by anti-CD44-immunoprecipitation followed by immunoblotting with anti-Nanog antibody (a) or anti-Stat-3 antibody (b) or anti-phospho- ] antibody (c) or reblotting with anti-CD44 (d) as a loading control using HSC-3 cells treated with no HA or with HA (50 mg/ml) for 5 min or pretreated with anti-CD44 antibody for 1 h followed by 5 min HA (50 mg/ml) addition. (Figure 1) ). To this end, we performed a HA-mediated Stat-3 tyrosine phosphorylation time course (for example, 0, 5, 15 and 60 min) using anti-CD44-mediated immunoprecipitation followed by anti-Stat-3[pY705] immunoblot or anti-CD44 immunoblot, respectively. Our results indicate that the association of phosphorylated Stat-3 with CD44 occurs as early as 5 min following HA addition to HNSCC cells ( Figure 1B) .
Next, we investigated whether there is an interaction between Nanog and total Stat-3 in the CD44-associated signaling complex in HNSCC cells (for example, HSC-3 cells ( Figure 1C) ). Specifically, we performed anti-CD44-mediated immunoprecipitation followed by antiNanog immunoblot or anti-total Stat-3/anti-Stat-3[pY705] immunoblot or anti-CD44 immunoblot ( Figure 1C ), respectively, using cells treated with HA or without HA. Our results indicate that a 5 min HA treatment causes the recruitment of Nanog and total Stat-3 (together with tyrosine phosphorylated Stat-3) (Figure 1Ca -c) into the CD44 complex ( Figure 1Cd ). In contrast, a low level of Nanog or Stat-3 (or tyrosine phosphorylated Stat-3) is present in the anti-CD44-immunoprecipitated materials (reblotted with anti-CD44) in cells not treated with HA (Figure 1Ca-d ) or in cells pretreated with anti-CD44 antibody followed by a 5 min HA treatment (Figure 1Ca-d) . These findings clearly establish that CD44, Nanog and Stat-3 (in particular, tyrosine phosphorylated Stat-3) are closely associated with each other, and that there is a significant increase in the recruitment of Nanog, Stat-3 (also phosphorylated Stat-3) into the CD44-associated complex following a 5 min HA treatment of HSC-3 cells.
Elucidation of Nanog/Stat-3 nuclear translocation, complex formation and transcription activation in HNSCC cells following HA-CD44 binding Several studies have suggested the importance of HA/CD44-mediated nuclear translocation of transcription factors in regulating target gene expression and tumor cell activation (Bourguignon et al., , 2009a . In this study using immunofluorescence staining and confocal microscopy, we observed that both Nanog and Stat-3 can be translocated from the cytosol to the nucleus after 15 min HA treatment ( Figure 2A ). In contrast, the majority of Nanog and Stat-3 is distributed in the cytosol and only a low level of Nanog and Stat-3 is present in the nucleus of HSC-3 cells, either pretreated with anti-CD44 antibody plus HA (Figure 2A ) or without any HA treatment ( Figure 2A ). These observations indicate that HA-CD44 interaction promotes Nanog and Stat-3 nuclear translocation in HNSCC cells.
In order to examine whether Nanog interacts with Stat-3 (in particular, tyrosine phosphorylated Stat-3) directly in the nucleus of HSC-3 cells, we analyzed the anti-Nanog-mediated immunoprecipitates from nuclear extracts by immunoblotting with anti-total Stat-3/antiphosphorylated Stat-3[pY705] or anti-Nanog antibody. Our results demonstrate that very little amount of Nanog is complexed with either total Stat-3 or tyrosine phosphorylated Stat-3 in the nuclear fractions of HSC-3 cells without any HA treatment (Figure 2Ba -c). Importantly, we observed that a 15 min HA treatment of HSC-3 cells stimulates a measurable increase in the amount of Nanog and total Stat-3/tyrosine phosphorylated Stat-3 complexes (Figure 2Ba-c) in the nuclear fractions of HSC-3 cells. When these tumor cells were pretreated with anti-CD44 antibody followed by a 15 min HA treatment, the complex formation between Nanog and total Stat-3/tyrosine phosphorylated Stat-3 in the nuclear fraction is greatly reduced in HSC-3 cells (Figure 2Ba -c). These findings suggest that Nanog is capable of forming a complex with Stat-3 (in particular, tyrosine phosphorylated Stat-3) (in the nucleus) in a HA-dependent and CD44-specific manner in HSC-3 cells.
Role of Stat-3 in regulating miR-21 expression in HA/CD44 and Nanog-activated HSC-3 cells In vivo binding of Stat-3 to the upstream/enhancer region of the miR-21 promoter in HSC-3 cells. A previous study indicated that the gene encoding oncogenic miR-21 is regulated by an upstream/enhancer promoter containing Stat-3 binding sites (Lo¨ffler et al., 2007 ) . To examine whether Nanog-associated Stat-3 directly interacts with the upstream/enhancer region of miR-21 promoter, anti-Stat-3 antibody-, anti-phospho-Stat-3 [pY 705 ] and anti-Nanog antibody-specific chromatin immunoprecipitation (ChIP) assays were performed in HSC-3 cells. As shown in Figure 3 , the PCR from both anti-Stat-3, anti-phospho-Stat-3 [pY 705 ], and anti-Nanog- Figure 2 Immunocytochemical and biochemical analyses of HA/CD44-induced Nanog and Stat-3 nuclear translocation in HSC-3 cells. (A) Immunostaining of Nanog (using Texas Red-labeled anti-Nanog (red color) and Stat-3 using FITC-labeled anti-Stat-3 (green color)): HSC-3 cells (untreated or pretreated with anti-CD44 antibody for 1 h) were incubated with HA (50 mg/ml) (or without HA) for 15 min at 37 1C and fixed by 2% paraformaldehyde. Subsequently, these cells were rendered permeable by ethanol treatment and immunostained with Texas Red-labeled anti-Nanog (red color) or FITC-labeled anti-Stat-3 (green color) and DAPI (a nuclear marker) (c) as described in Materials and methods. (B) Analyses of HA/CD44-induced Nanog and Stat-3 complex formation in the nuclear fraction: HSC-3 cells (untreated or pretreated with anti-CD44 antibody for 1 h) were incubated with HA (50 mg/ml) (or without HA) for 15 min at 37 1C. Nuclear fractions of these cells were then prepared by anti-Nanog immunoprecipitation followed by immunoblotting with anti-Stat-3 antibody (a) or anti-phospho-Stat-3 [pY 705 ] (b) or reblotting with anti-Nanog (c) as a loading control as described in Materials and methods (untreated cells (ÀHA); cells treated with HA ( þ HA) for 15 min; lane 3: cells pretreated with anti-CD44 antibody for 1 h plus 15 min HA addition (anti-CD44 þ HA)). (The ratio of Stat-3 or phosphorylated Stat-3 and Nanog (the loading control) (d) was determined by densitometry, and the levels were normalized to untreated (no HA treatment) value (designated as 1.00); the values expressed represent an average of triplicate determination of three experiments with an SD of o5%). . These findings suggest that the recruitment of Stat-3 (also phospho-Stat-3) and Nanog into the region of miR-21 promoter site is HA-specific and CD44-dependent. To confirm the direct involvement of Stat-3 and Nanog in miR-21 gene upregulation, both Stat-3 and Nanog were first downregulated by Stat-3 small interfering RNA (siRNA) or Nanog siRNA, respectively, followed by the miR-21 promoter-specific ChIP assay as described above. Our results indicate that transfection of HNSCC cells with Nanog siRNAs (Figure 3Aa In order to establish the specificity of the Stat-3/ Nanog siRNAs used in this study, HSC-3 cells were transfected with siRNA sequences targeting human Nanog or Stat-3 followed by immunoblotting with anti-Stat-3 antibody or anti-Nanog antibody, respectively. Our results clearly indicate that Stat-3 siRNA target sequences successfully suppress the expression of Stat-3 (but not Nanog) in HNSCC cells (Figure 3Ba-c) , whereas Nanog siRNA target sequences effectively block Nanog (but not Stat-3) expression in HNSCC cells ( Figure 3B-a-c) . In control samples, neither Stat-3 nor Nanog is downregulated in HSC-3 cells treated with transfection reagents containing scrambled siRNA (Figure 3Ba-c) . Therefore, we conclude that the downregulation of Stat-3 or Nanog expression by either Stat-3 siRNA or Nanog siRNA used in our study is specific.
Production of miR-21 in HNSCC cells. The expression of mature miR-21 has been shown to be involved in HNSCC progression (Volinia et al., 2006; Chang et al., 2008) . To determine whether miR-21 levels are increased following the binding of HA to CD44, we first prepared small RNAs followed by an RNase protection assay using the miRNA Detection Kit (Ambion, Foster City, CA, USA). Our results indicate that the level of miR-21 is increased in HSC-3 cells treated with scrambled sequence siRNA plus HA (Figure 4a These findings support the notion that both Nanog and Sta-3 are required for miR-21 production in HA-activated HNSCC cells. We also noted that the increase of miR-21 expression was specifically a result of the interaction between HA and CD44 as pretreatment of HSC-3 cells with anti-CD44 antibody plus HA addition significantly reduces miR-21 production (Figure 4a-lane 3) . Moreover, we have found that the expression of miR-21 can be induced in cells treated with a miRNA-negative control upon addition of HA (Figure 4a -lane 7 vs lane 6). In contrast, the treatment of HSC-3 cells with an anti-miR-21 inhibitor plus HA results in a decrease in miR-21 expression (Figure 4a-lane 8) . We believe that these changes in miR-21 expression under various treatment conditions was not due to the variations of RNA extracted from each sample as there were very similar levels of the miR-191 control in all samples (Figure 4b-lane 1-8) . Together, these findings strongly suggest that HA/CD44-activated Nanog and Stat-3 signaling has an important role in the production of miR-21 in HNSCC cells.
The impact of HA/CD44-mediated miR-21 (induced by Nanog and Stat-3 signaling) in PDCD4/IAP expression, anti-apoptosis and chemoresistance in HSC-3 cells PDCD4 was identified as one of the tumor suppressor genes induced by miR-21 (Asangani et al., 2008) . IXIAPc-IAP-1, c-IAP-2 and XIAP) is linked to chemoresistance by their binding to caspases and suppressing apoptosis (Hunter, 2007) . Here,we demonstrate that basal levels of PDCD4 expression and IAPs were detected in cells treated with scrambled sequence siRNA without HA addition ( Figure 5a (Table 1a ). These observations strongly suggest that HA causes both a decrease in apoptosis and an increase in tumor cell growth and survival (Table 1a) leading to the enhancement of chemoresistance (Table 1a) . Moreover, downregulation of Nanog, Stat-3 or miR-21 (by treating HSC-3 cells with Nanog siRNA or Stat-3 siRNA, or transfected HSC-3 cells with an anti-miR-21 inhibitor (but not scrambled sequence siRNA or with miRNA-negative control)) effectively attenuates HA-mediated tumor cell growth/anti-apoptosis/survival and enhances multidrug sensitivity in HSC-3 cells (Table 1a ). These findings suggest that the HA/CD44-mediated Nanog/Stat-3 signaling pathways and miR-21 function may represent new targets to cause tumor cells to undergo apoptosis/ death and overcome chemotherapy resistance in head and neck cancer cells. Apparently, both PDCD4 loss and IAP protein gain are responsible for HA-mediated cisplatin resistance in HNSCC cells ( Figure 5 ). Recently, a small molecule IAP protein inhibitor (bivalent SM-164) has been shown concurrently to target cIAP-1/cIAP-2 for degradation and antagonize XIAP leading to an enhancement of tumor cell apoptosis and tumor regression (Lu et al., 2008) . In this study, we have found that chemosensitivity increases with a newly developed IAP protein inhibitor, SM164 (Table 1b) . These findings suggest that the use of a combination of IAP protein inhibitor (SM164) and cisplatin may improve the efficacy of chemotherapeutic drug treatments for head and neck cancer.
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Discussion
The primary tumor type in head and neck cancer is squamous cell carcinoma (HNSCC). These tumor cells display persistent cell growth leading to chemoresistance and recurrence (Parkin et al., 2005) . Hyaluronan, the major glycosaminoglycan found in the extracellular matrix of mammalian tissues, is now considered to be a physiologically-relevant ligand for CD44 (also known as a hyaluronan receptor) in many cell types, including HNSCC cells (Wang and Bourguignon, 2011) . Most of malignant solid tumors display high levels of both HA and CD44 (Toole and Hascall, 2002; Wang and Bourguignon, 2011) . HA-CD44 interaction has been shown to promote oncogenic signaling and tumor cell-specific properties (Turley et al., 2002; Bourguignon, 2008) . In this study, we focused on determining which oncogenic pathways are directly involved in regulating HA and CD44-specific HNSCC cell behaviors such as chemotherapy resistance.
Nanog has been suggested as one of the major factors that render the reprogramming adult stems into germline-competent induced pluripotent stem cells (Kashyap et al., 2009) . It is expressed not only in germ cell tumors, but also found to be expressed in many other tumors, including HNSCC cells and tissues (Chiou et al., 2008) . In this study, we also detected Nanog expression in HNSCC cells (for example, HSC-3 cells) (Figures 1  and 2 ). The fact that Nanog overexpression is closely associated with HNSCC cells and tissues suggests that its expression may be implicated in self-renewal and tumorigenesis via activating its downstream target genes. The question of how Nanog signaling pathway has a role in regulating HNSCC cell activation has not been well understood. Overexpression of miR-21 is detected in various HNSCC cell lines and patient specimens (Volinia et al., 2006; Chang et al., 2008) . Accumulating evidence indicates that miR-21 is closely associated with both cancer development and chemotherapy resistance (Bourguignon et al., 2009a ). Nanog appears to be involved in the regulation of pri-miRNA expression during cancer development (Bourguignon et al., 2009a) . Our previous work showed that HA/CD44-activated PKCe promotes Nanog interaction with p68 and DROSHA leading to biosynthetic processing and production of miR-21 in breast tumor cells (Bourguignon et al., 2009a) . These findings suggest that HA/CD44-mediated Nanog signaling is closely linked to miR-21 production and function during oncogenesis.
Abnormal Stat-3 signaling appears to have a critical role in oncogenesis (Huang, 2007) . In particular, constitutive activation of Stat-3s such as tyrosine phosphorylated Stat-3 has been observed in human malignancies, including HNSCC (Huang, 2007) . Previous studies showed that the functional link between Nanog and Stat-3 exists in several different tumor cells . In this study, we observed that HA-CD44 binding activates Nanog/Stat-3 (also tyrosine phosphorylated Stat-3) nuclear localization and complex formation in HSC-3 cells (Figures 1, 2 and 3) . Thus, be very important for the understanding of the disease mechanism occurring during HNSCC progression. Lo¨ffler et al., 2007) .
Here, we have provided new evidence that HA/CD44 activates Nanog-Stat-3 (also phosphorylated Stat-3) complex formation and nuclear translocation in HNSCC cells (Figures 1 and 2) . Our results also indicate that miR-21 is controlled by an upstream promoter/enhancer containing Stat-3 binding sites in HNSCC cells, while ChIP assays demonstrate that stimulation of miR-21 production by HA is Nanog/Stat-3 complex-dependent in HNSCC cells (Figure 3) . Most importantly, an anti-miR-21 inhibitor can enhance PDCD4 expression ( Figure 5) , and block HA/CD44-mediated tumor functions (for example, survival protein expression (Figure 5 ), tumor cell growth and survival/chemotherapy resistance (Table 1) ) in HNSCC cells. Thus, this newly discovered HA/CD44-Nanog/Stat-3 signaling pathway and miR-21 production/function are highly innovative and should provide important new drug targets to cause tumor cell apoptosis and overcome chemotherapy resistance in head and neck cancer cells.
Cisplatin is the most common anti-head and neck chemotherapy used today. The ability of this drug to induce tumor cell death is often counteracted by the presence of anti-apoptotic regulators leading to chemoresistance (Nakamura et al., 2005; Torre et al., 2010; Wang and Bourguignon, 2011) . Several lines of evidence point toward the IAP family (for example, c-IAP-1, c-IAP-2 and XIAP) playing a role in oncogenesis via their effective suppression of apoptosis (Hunter, 2007) . The mode of action of IAPs in suppressing apoptosis appears to be through direct inhibition of caspases and pro-caspases (primarily caspase 3 and 7) (Hunter, 2007) . IAPs also support chemoresistance by preventing tumor cell death induced by anticancer agents (Gyrd-Hansen and Meier, 2010) . Although certain anti-apoptotic proteins (for example, Bcl-xL) have been shown to participate in anti-apoptosis and chemoresistance in HA/CD44-activated breast tumor cells (Bourguignon et al., 2009b) , the involvement of IAPs in HA/CD44-mediated HNSCC cell survival and chemoresistance has not been fully elucidated.
In this study, we demonstrated that HA/CD44-activated Nanog/Stat-3 signaling and miR-21 reduce PDCD4 expression ( Figure 5 ) resulting in oncogenesis (by enhancing the expression of inhibitors of antiapoptosis proteins (IAPs) (Figure 5) ). Furthermore, downregulation of HA/CD44-activated Nanog/Stat-3 signaling (by Nanog siRNA/Stat-3 siRNA) and miR-21 production (by anti-miR-21 inhibitor) not only induces PDCD4 upregulation ( Figure 5 ) but also inhibits the expression of survival proteins (for example, c-IAP-1, c-IAP-2 and XIAP) ( Figure 5 ). Subsequently, these signaling perturbation events contribute to apoptosis and chemosensitivity (Table 1) . Our preliminary data indicate that (i) PDCD4 downregulation can be detected as early as 30-60 min after HA binding to CD44, whereas IAP protein upregulation can be detected 5-6 h after HA-CD44 interaction; and (ii) PDCD4 overexpression blocks IAP protein expression. After 24 h of HA addition, a maximal level of PDCD4 loss and IAP overexpression can be reached in HNSCC cells. Therefore, this time point was used in Figure 5 . However, the cellular and molecular mechanisms involved in the regulation of these causal links between Nanog/Stat-3 signaling and miR-21 function including PDCD4 dowregulation, IAP upregulation, anti-apoptosis and chemoresistance will need to be resolved by further experiments.
As summarized in Figure 6 , we propose that HA binding (step 1) promotes CD44 association with Nanog and Stat-3 (also tyrosine phosphorylated Stat-3) (step 2). Nanog and Stat-3 (also phosphorylated Stat-3) then translocate from the cytosol to the nucleus (step 3) and interacts with an upstream/enhancer region (containing Stat-3 binding sites) of miR-21 (step 4), resulting in miR-21 gene expression and mature miR-21 production (step 5). The resultant miR-21 then functions to downregulate the tumor suppressor protein (PDCD4) (step 6a) and promotes HNSCC cell activation (step 7a) leading to IAP (c-IAP-1, c-IAP-2 and XIAP) expression, HNSCC cell anti-apoptosis/survival and chemoresistance. In direct contrast, treatment of HNSCC cells with an anti-miR-21 inhibitor induces tumor suppressor protein (PDCD4) upregulation (step 6b). Subsequently, these changes result in the inhibition of IAP (c-IAP-1, c-IAP-2 and XIAP) expression (step 7b), stimulation of apopto-sis and enhancement of chemosensitivity in HNSCC cells. Taken together, these findings suggest that targeting HA/CD44-mediated Nanog-Stat-3 signaling pathways and miR-21 function may provide a new drug target to sensitize tumor cell apoptosis/death and overcome chemotherapy resistance in HNSCC cells.
Materials and methods
Cell culture
The cell line, HSC-3 cells (Japan Cancer Research Resources Bank, Tokyo), was established in 1985 from a primary oral squamous cell carcinoma removed from the tongue of a 64-year-old male patient. The HSC-3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cells were routinely serum starved (and therefore deprived of serum HA) before adding HA.
Antibodies and reagents
Monoclonal rat anti-CD44 antibody (Clone: 020; Isotype: IgG 2b ; obtained from CMB-TECH Inc., San Francisco, CA, USA) recognizes a determinant of the HA-binding region common to CD44 and its principal variant isoforms. This rat anti-CD44 was routinely used for HA-related blocking experiments and immunoprecipitation. Immunoreagents such as rabbit anti-Stat-3 antibody, goat anti-Nanog antibody, mouse anti-PDCD4 antibody and goat anti-actin antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Mouse anti-c-IAP-1 antibody, mouse anti-c-IAP-2 and mouse anti-XIAP antibody were from BD (Franklin Lakes, NJ, USA). Rabbit anti-phospho- ], tyrosine 705 residue) was from Cellular Signaling Technology (Beverly, MA, USA). Cisplatin was obtained from Sigma Chemicals (St Louis, MO, USA). Healon HA polymers (B500 000 Da polymers) were purchased from Pharmacia & Upjohn Company (Kalamazoo, MI, USA) and were prepared by gel filtration chromatography using a Sephacryl S1000 column (GE Healthcare Biosciences, Uppsala, Sweden).
Anti-miR-21 inhibitor preparation and transfection Anti-miR targeting miR-21 (anti-miR-21 inhibitor) (Ambion, catalog number, 17000) and its corresponding negative control (Ambion, catalog number, 17010) were transfected into HSC-3 cells using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) for 24 h. Cells were then treated with HA or without HA in various experiments as described below. The final concentrations of anti-miR-21 inhibitor and miRNAnegative control used in various experiments were 30 nmol/l.
Immunoprecipitation and immunoblotting techniques
Immunoprecipitation was conducted after homogenization of the cell lysate using rat anti-CD44 antibody followed by goat anti-rat IgG-beads. Subsequently, the immunoprecipitated materials were immunoblotted with rabbit anti-Nanog antibody (2 mg/ml) or rabbit anti-Stat-3 antibody (2 mg/ml) or rabbit anti-phospho- ] (2mg/ml). The nuclear fraction (using the extraction kit from Active Motif (Carsbad, CA, USA)) of HSC-3 cells (untreated or pretreated with anti-CD44 antibody) plus 50 mg/ml HA (or no HA) for various time intervals (for example, 0, 5 min, 15 min or 60 min) at 37 1C was also used for goat anti-Nanog antibody-conjugated immunoprecipitation followed by rabbit anti-Stat-3-mediated immunoblot, respectively.
In some cases, cell lysate of HSC-3 cells (pretreated with anti-CD44 antibody or transfected with Nanog siRNA or Stat-3 siRNA or siRNA with scrambled sequences; or anti-miR-21 inhibitor or miRNA-negative control; or without any treatment) followed by HA (50 mg/ml) addition (or no HA addition) for various time intervals (for example, 0, 5, 10, 15, 30, 60 min or 24 h) at 37 1C) were also immunoblotted using various immuno-reagents (for example, mouse anti-PDCD4 (2 mg/ml) or mouse anti-c-IAP-1 or mouse anti-c-IAP-2 
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Figure 6 A proposed model for HA/CD44-mediated Nanog and Stat-3 signaling in the regulation of miRNA-21 production, oncogenesis and chemoresistance in HNSCC cells. The binding of HA to CD44 (step 1) promotes a complex formation between Nanog/Stat-3 (also tyrosine phosphorylated Stat-3, p-Stat-3) and CD44 (step 2). Both Nanog and Stat-3 (p-Stat-3) then translocate from the cytosol to the nucleus and interacts with the Stat-3 binding sites located at the upstream promoter/enhancer region of miR-21 (step 4), resulting in miR-21 gene expression and mature miR-21 production (step 5). The resultant miR-21 then functions to downregulate the tumor suppressor protein (PDCD4) (step 6a, indicated by the arrow with solid lines) and promote HNSCC activation leading to IAP (c-IAP-1, c-IAP-2 and XIAP) expression, HNSCC cell anti-apoptosis/survival and chemoresistance (step 7a, indicated by the arrow with solid lines). In direct contrast, treatment of HNSCC cells with an anti-miR-21 inhibitor induces tumor suppressor protein (PDCD4) upregulation (step 6b, indicated by the arrow with dash lines). Subsequently, these changes result in HNSCC cell inactivation including inhibition of IAP (c-IAP-1, c-IAP-2 and XIAP) expression (step 7b, indicated by the arrow with dash lines), stimulation of apoptosis and enhancement of chemosensitivity in HNSCC cells. This newly discovered Nanog/Stat-3 signaling pathway leading to miR-21 functioning should provide important drug targets for sensitizing tumor cell apoptosis and overcome chemoresistance in HA/CD44-activated head and neck cancer cells.
antibody and anti-XIAP (2 mg/ml) or goat anti-actin (2 mg/ml) (as a loading control), respectively).
Chromatin immunoprecipitation assay
To examine whether Nanog-Stat-3 complex directly interacts with the upstream promoter/enhancer region of miR-21, ChIP assays were performed in HNSCC cells (pretreated with anti-CD44 antibody or transfected with Nanog siRNA or Stat-3 siRNA or siRNA with scrambled sequences) treated with HA (50 mg/ml) or without HA using a kit (EZ ChIP) from Millipore Corp., Billerica, MA, USA according to the manufacturer's instructions. Crosslinked chromatin lysates were sonicated and diluted with ChIP sonication buffer plus protease inhibitors, divided and incubated with normal rabbit IgG or rabbit anti-Nanog antibody or rabbit anti-Stat-3 antibody or rabbit anti-phospho-Stat-3 [pY 705 ] antibody at 4 1C overnight, then precipitated with protein G agarose. Crosslinking was reversed by overnight at 65 1C incubation; DNA fragments were then extracted with PCR purification kit, analyzed by PCR and quantitated by real-time PCR using primer pairs specific for the miR-21 upstream promoter/ enhancer region containing the Stat-3 binding sites: forward primer: 5 0 -CTGGGAGAAACCAAGAGCTG-3 0 and reverse primer: AGGGGACAAGTCAGAGAGAGG-3 0 on an agarose gel as described previously (Lo¨ffler et al., 2007) .
RNase protection assay analysis of mature miRNAs Expression of miRNAs was qualitatively analyzed by RNase protection assay. For RNase protection assay, enriched small RNA isolated from HSC-3 cells (transfected with scrambled sequence siRNA with (or without) anti-CD44 antibody or transfected with Nanog siRNA or Stat-3 siRNA or siRNA or anti-miR-21 inhibitor or miRNA-negative control in the presence or absence of HA for various time intervals (for example, 0, 5 min, 10 min, 15 min, 30 min or 2 h) at 37 1C) was enriched and purified using the mirVana miRNA Isolation kit (Ambion). RNA concentrations were verified by measuring absorbance (A 260 ) on the NanoDrop Spectrophotometer ND-1000 (NanoDrop, Wilmington, DE, USA). The mirVana miRNA probe construction kit (Ambion) was used to synthesize the 32 P-labeled miR-21 antisense probe and miR-191 probe loading control as described previously (Bourguignon et al., 2009a) .
Immunofluorescence staining HSC-3 cells (untreated or pretreated with anti-CD44 antibody) were incubated with HA (50 mg/ml) at 37 1C for various time intervals (for example, 0, 10, 30 or 60 min) or with no HA. These cells were then fixed with 2% paraformaldehyde. Subsequently, these cells were rendered permeable by ethanol treatment followed by incubating with Texas Red-conjugated anti-Nanog antibody and fluorescein (FITC)-conjugated antiStat-3 antibody followed by DAPI staining (a marker for nucleus). To detect nonspecific antibody binding, DAPI-labeled cells were incubated with FITC or Texas Red-conjugated normal IgG, respectively. No labeling was observed in control samples. These fluorescence-labeled samples were then examined with a confocal laser scanning microscope. The presence of X80% cancer cells in the procured samples was confirmed by a clinical pathologist as described previously (Wang et al., 2009) .
Clinical tumor samples
Immunohistochemistry
The tissue specimens were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 24 h at 4 1C and embedded in paraffin. Tissue sections of 5 mm thickness were placed on positively charged glass slides (Fisher Scientific, Pittsburgh, PA, USA). Immunohistochemical stains were performed using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA), according to the manufacturer's protocol. Rabbit anti-Nanog antibody or rabbit anti-Stat-3 antibody (dilution factor from 1 : 100 up to 1 : 1000 determined by titration) was applied to tissue sections and incubated overnight at 4 1C. Secondary biotinylated antibody and streptavidin-HRP conjugate complex were applied for 60 and 30 min, respectively. After washing in buffer, the chromogen diaminobenzidine was applied for 5 min followed by a counterstain with Mayer's hematoxylin. Negative controls included substituting the primary antisera with preimmune sera from the same species and omitting the primary antibody, or by using an antibody of irrelevant specificity. In some cases, these clinical samples were also incubated with Texas Red-conjugated anti-Nanog antibody and fluorescein (FITC)-conjugated anti-Stat-3 antibody or rabbit anti-phospho-Stat-3 [pY 705 ] antibody, respectively. To detect nonspecific antibody binding, HNSCC tumor sections were also incubated with FITC or Texas Red-conjugated normal IgG, respectively. No labeling was observed in control samples. These fluorescence-labeled samples were then examined with a confocal laser scanning microscope.
Tumor cell growth and apoptosis assays HSC-3 cells were transfected with either scrambled sequence siRNA or with Nanog siRNA (or Stat-3 siRNA) or anti-miR-21 inhibitor or miRNA-negative control or pretreated with anti-CD44 antibody, as above. Some cells were also treated with an IAP inhibitor, SM164 (2 nM) or vehicle control. These cells (5 Â 10 3 cells/well) were then incubated with various concentrations of cisplatin (4 Â 10 À9 M-1.75 Â 10 À5 M) with no HA or with HA (50 mg/ml). After 24 h incubation at 37 1C, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based growth assays were analyzed as described previously (Bourguignon, 2008 (Bourguignon, , 2009a . The percentage of absorbance relative to untreated controls (that is, cells treated with neither HA nor chemotherapeutic drugs) was plotted as a linear function of drug concentration. The 50% inhibitory concentration (IC 50 ) was identified as a concentration of drug required to achieve a 50% growth inhibition relative to untreated controls. For apoptosis assay, FITC-conjugated Annexin V (for measuring apoptotic cells) using Apoptosis Detection Kit (Calbiochem, San Diego, CA, USA) was used according to the manufacturer's protocol (Bourguignon et al., 2009b) .
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